Abuse filter log

Details for log entry 272,438

17:56, 24 April 2021: CalebHyder6244 (talk | contribs) triggered filter 0, performing the action "edit" on Eli Lilly Forecasts 2019 Profit Revenue Above Estimates. Actions taken: Disallow; Filter description: (examine)

Changes made in edit

Action parameters

Variable	Value
Name of the user account `(user_name)`	'CalebHyder6244'
Age of the user account `(user_age)`	63117
Groups (including implicit) the user is in `(user_groups)`	[ 0 => '*', 1 => 'user', 2 => 'autoconfirmed' ]
Page ID `(page_id)`	0
Page namespace `(page_namespace)`	0
Page title (without namespace) `(page_title)`	'Eli Lilly Forecasts 2019 Profit Revenue Above Estimates'
Full page title `(page_prefixedtitle)`	'Eli Lilly Forecasts 2019 Profit Revenue Above Estimates'
Action `(action)`	'edit'
Edit summary/reason `(summary)`	''
Old content model `(old_content_model)`	''
New content model `(new_content_model)`	'wikitext'
Old page wikitext, before the edit `(old_wikitext)`	''
New page wikitext, after the edit `(new_wikitext)`	'<br>Dec 19 (Reuters) - Drugmaker [http://imageshack.us/photos/Eli%20Lilly Eli Lilly] and Co on Wednesday forecast 2019 revenue and adjusted profit above analysts' expectations, citing higher demand for newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.<br> <br>Trulicity, which recently overtook Humalog as Lilly's top-selling medicine, had sales of $816.2 million and helped power Lilly's profit beat in the third quarter.<br> <br>The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with average analysts' estimates of $5.82 per share, according to IBES data from Refinitiv.<br> <br>Lilly said revenue was expected to be between $25.3 billion and $25.8 billion for the coming year, also above analysts' expectations of $24.77 billion.<br> <br>However, the drugmaker said sales of erectile dysfunction drug [https://cialisahc.com/ cialis cheapest price canada] will take a hit due to loss of patent exclusivity.<br> <br>The Indianapolis-based company also reiterated its forecast for 2018 adjusted profit.<br> <br>Shares of the drugmaker, which raised its quarterly dividend by 15 percent, were up 1 pct at $107.60 in light premarket trading.<br><br>(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)<br>'
Old page size `(old_size)`	0
All external links added in the edit `(added_links)`	[ 0 => 'http://imageshack.us/photos/Eli%20Lilly', 1 => 'https://cialisahc.com/' ]
All external links in the new text `(all_links)`	[ 0 => 'http://imageshack.us/photos/Eli%20Lilly', 1 => 'https://cialisahc.com/' ]
Links in the page, before the edit `(old_links)`	[]
Unix timestamp of change `(timestamp)`	1619286960


			<br>Dec 19 (Reuters) - Drugmaker [http://imageshack.us/photos/Eli%20Lilly Eli Lilly] and Co on Wednesday forecast 2019 revenue and adjusted profit above analysts' expectations, citing higher demand for newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.<br> <br>Trulicity, which recently overtook Humalog as Lilly's top-selling medicine, had sales of $816.2 million and helped power Lilly's profit beat in the third quarter.<br> <br>The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with average analysts' estimates of $5.82 per share, according to IBES data from Refinitiv.<br> <br>Lilly said revenue was expected to be between $25.3 billion and $25.8 billion for the coming year, also above analysts' expectations of $24.77 billion.<br> <br>However, the drugmaker said sales of erectile dysfunction drug [https://cialisahc.com/ cialis cheapest price canada] will take a hit due to loss of patent exclusivity.<br> <br>The Indianapolis-based company also reiterated its forecast for 2018 adjusted profit.<br> <br>Shares of the drugmaker, which raised its quarterly dividend by 15 percent, were up 1 pct at $107.60 in light premarket trading.<br><br>(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)<br>